This Healthcare Stock Is 1 of the Hottest Buys on the TSX

Jamieson Wellness (TSX:JWEL) is a pandemic-proof stock that is outperforming the market. Plenty of growth is ahead for the healthcare stock.

| More on:
Pills spilling out of a prescription pot

Image source: Getty Images.

Founded in 1922, Jamieson Wellness (TSX:JWEL) is the leading manufacturer and distributor of high-quality natural health products in Canada, including vitamins, herbal extracts, and skincare products. It is one of the country’s most trusted vitamin brands. Jamieson is one of the best stocks you can buy on the TSX right now.

The company has been incredibly resilient since the start of the pandemic. Sales of vitamins and supplements aren’t impacted by a recession. The pandemic has even helped to boost sales, as people are becoming more health conscious. An aging population is also positive for Jamieson, as older people tend to buy more health supplements than younger people.

Jamieson had a strong second quarter

In the second quarter, revenue increased by 15.6% to $93.2 million, driven by 22.2% growth in Jamieson Brands. Net income was $6 million, and adjusted net income increased 25.1% to $9.9 million. Earnings per diluted share were $0.15, and adjusted earnings per diluted share were $0.24, beating estimates of $0.21.

Mark Hornick, president and CEO of Jamieson Wellness, said in a statement: “I am pleased that we continue to provide value to our investors, with sustained growth in revenue and earnings. We continue to drive our growth initiatives forward, increasing our outlook for both domestic and international revenue as well as for adjusted EBITDA and adjusted net earnings, and are confident in our near and long-term growth opportunities.”

The company’s board of directors authorized a 1.5 cent increase in the quarterly dividend and declared a cash dividend for the second quarter of 12.5 cents per common share.

Sales are growing fast

The company’s domestic Jamieson Brands sales increased by 14%, or $7.3 million, reflecting higher sales due to increased demand for immunity and general health supplements. The company’s international operations generated significant growth, increasing 69%, or $6.2 million from a year earlier, driven by strong growth in multiple geographies, as demand for immunity products increased significantly, especially in China and Europe.

China continues to lead international growth with increased cross-border e-commerce sales and initial shipments to domestic retail stores as the distribution network is expanded.

Jamieson increased its outlook for fiscal 2020 and forecasts sales of between $385 and $395 million compared to $364 to $376 million previously, representing annual growth of 11.5% to 14.5%. It now expects adjusted diluted earnings per share in a range of $1.08 to $1.15 compared to $1.02 to $1.10 previously. The increased outlook for the company reflects strong consumer demand both at home and abroad.

A low-risk growth stock

Jamieson is a pandemic-proof stock that will immunize your portfolio against a market downturn. You can buy and hold this low-risk growth stock for many years without worrying about your money.

This boring stock is in an unstoppable bull market. It has soared by 50% year to date and still has more upside. As the market for vitamins and supplements is growing fast, the future bodes well for Jamieson. Holding this stock is a good way to increase your wealth over the long term. It’s best to buy this stock in a TFSA or an RRSP to profit from its strong growth tax-free.

The stock’s valuation is currently a little high but looks justified given the leading position Jamieson occupies in the market.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Stephanie Bedard-Chateauneuf has no position in any of the stocks mentioned.

More on Investing

Safety helmets and gloves hang from a rack on a mining site.
Metals and Mining Stocks

Here Are 3 Phenomenal Reasons to Buy Lundin Stock Right Now

Lundin stock (TSX:LUN) has seen its share price climb higher from external and internal factors that are enough to make…

Read more »

thinking
Stocks for Beginners

Can Waste Connections Stock Keep Beating Estimates?

WCN (TSX:WCN) stock missed its own estimates last year but provided strong guidance for 2024. So, here's what to watch…

Read more »

financial freedom sign
Dividend Stocks

The Dividend Dream: 23% Returns to Fuel Your Income Dreams

If you want growth and dividend income, consider this dividend stock that continues to rise higher after October lows.

Read more »

You Should Know This
Top TSX Stocks

3 Things About Couche-Tard Stock Every Smart Investor Knows

Alimentation Couche-Tard (TSX:ATD) stock may sustain a growth trajectory in two ways. However, smart investors appreciate one growing risk.

Read more »

IMAGE OF A NOTEBOOK WITH TFSA WRITTEN ON IT
Tech Stocks

The Ultimate Growth Stocks to Buy With $7,000 Right Now

These two top Canadian stocks have massive growth potential, making them two of the best to buy for your TFSA…

Read more »

edit U-turn
Bank Stocks

TD Stock: Why I Reversed Course

Toronto-Dominion Bank (TSX:TD) is one stock I reversed course on in a big way.

Read more »

railroad
Dividend Stocks

Here’s Why CNR Stock Is a No-Brainer Value Stock

Investors in Canadian National Railway (TSX:CNR) stock have had a great year, and here's why that trajectory can continue.

Read more »

A shopper makes purchases from an online store.
Tech Stocks

Down 21%, Is Shopify Stock a Buy on the TSX Today?

Shopify (TSX:SHOP) stock certainly rose in 2023 but is now down 21% from 52-week highs. So, is it a buy…

Read more »